Trust center

How DoseRank ranks

Every ranking on DoseRank carries its reasoning. This page publishes the full method — how a goal becomes a ranked list, how evidence is judged, what refreshes the data, the policies that keep placement honest, and every change to the model.

Model v2.1Placement is never paid
Ranking methodology

From goal to ranked list

DoseRank starts with an outcome, not a brand. Four steps turn a goal like “sleep better” into an explainable, ranked shelf of products.

1

Outcome matching

Your goal is mapped to a predefined health outcome — never a SKU or a keyword. Every product relevant to that outcome enters the pool, before any availability or relevance filtering.

2

Ingredient form scoring

Each ingredient form is scored separately for the outcome — magnesium glycinate and magnesium oxide are different answers. Form scores come from the ingredient–outcome evidence map.

3

Product scoring

The label’s per-serving dose is checked against the studied effective window (dose fit), then blended with the ingredient evidence strength and study confidence into the Clinical score.

4

Ranking

Products are ordered by the composite DoseRank score — the clinical score gated by product reliability signals: trust, value, and demand. The gate can only trim a score, never boost it.

Composite outcome score
The composite score, in two stagesWeights for model v2.1 — every change is logged in the changelog below

Stage 1 blends the clinical core: a weighted geometric mean of ingredient evidence, dose fit, and study confidence — where study confidence itself is 80% evidence volume and 20% effect size.

Ingredient evidence 55%Dose fit 30%Study confidence 15%

Stage 2 multiplies that clinical score by a reliability gate built from trust, value, and demand signals, with the emphasis value > trust > demand. The gate can only trim the clinical score, never boost it — the composite never exceeds the clinical score (composite ≤ clinical), so a product can’t out-market weak evidence.

DoseRank

Composite outcome score

Value

Clinical × Value × Trust

Trust

Clinical × Trust

Popularity

Clinical × Demand × Trust

Every lens re-ranks the same scored set — nothing is rescored to flatter a tab. When an outcome has a thin clinical pool, lens picks are labeled “· early signal”; the DoseRank composite is unaffected.

85–100 · StrongAt or near the top score for this outcome.
70–84 · MiddlingSolid, with a measurable gap to the strongest products.
Below 70 · TrailingMeaningfully behind the top-ranked products for this outcome.
The scores

A fixed vocabulary, defined once

The same seven terms appear on every score card, table, and comparison — no synonyms, no renamed metrics. This is the canonical definition of each.

CompositeHigher is better

The overall DoseRank score — a weighted blend of clinical strength, evidence, dose fit, trust and value.

Powered by clinical score × the reliability gate (trust, value, demand).

ClinicalHigher is better

How strongly the formula's ingredients and doses match what clinical studies used for this outcome.

Powered by ingredient–outcome evidence map × dose adequacy.

EvidenceHigher is better

How much published human research backs the formula's key ingredients for this outcome — both how many studies exist and how strong they are.

Powered by study count and study strength for the key ingredients.

Dose fit100 = squarely in range

How closely each key ingredient's dose sits inside the clinically studied range for this outcome.

Powered by label dose vs. the studied dose window, per ingredient.

TrustHigher is better

How well customers rate this product, with extra weight given to ratings backed by a large number of reviews.

Powered by customer ratings weighted by review count.

ValueHigher is better

How the price per serving compares with similar products for this outcome — 50 is the typical price, higher means better value for your money.

Powered by price per serving vs. similar products — median-anchored, 50 = typical.

PopularityHigher is better

How strongly this product sells compared with the other ranked products for this outcome.

Powered by sales strength vs. the other ranked products for this outcome.

Evidence standards

What counts as evidence

Scores move on published human research and verifiable product data — nothing else. When the evidence is thin, the ranking says so instead of guessing.

What moves a score

  • Human studies only

    Animal-only and in-vitro findings never raise a score. Evidence strength comes from published human research — how many studies exist and how strong they are.

  • Dose inside the studied window

    Dose fit rewards a per-serving dose that lands in the range studies actually used. Beyond that range, extra milligrams stop earning credit — the reward saturates at a bounded cap, so the biggest number never wins by default. Harmful or negative findings subtract from the evidence directly.

  • Trust from real customers

    Trust reflects how well customers rate a product, with extra weight for ratings backed by a large number of reviews — buyer signals on record, not marketing claims.

How evidence is labeled

  • Strong evidence

    A solid pool of direct human studies supports the ingredient–outcome link.

  • Early signal· early signal

    The clinical pool is thin. Lens picks carry this label so a weak signal is never dressed up as a verdict.

  • Not enough data

    Shown as “Not enough data for this view yet” — a gap is stated, never filled in.

What never moves a score

  • Payment from a brand

    There is no price for a position, a badge, or a mention.

  • Affiliate commission rates

    Commission terms are held apart from the ranking pipeline and never enter a score.

  • Marketing claims

    Front-of-label promises carry no weight. Only the supplement-facts panel is scored.

  • Ad spend or popularity alone

    Demand appears only inside the Popularity lens, and only multiplied by clinical strength.

Data freshness

Rankings carry their date

Prices, stock, and ratings drift. Every ranking snapshot is stamped, and gaps are named instead of hidden.

Recomputed stamp

Every ranking page shows its snapshot stamp

Rankings are recomputed after each crawl cycle, and the stamp is printed beside the results — never buried in a footer.

Recomputed after each crawl cycle · placement is never paid
Availability gate

Only in-stock products are ranked

Availability is an entry gate — only products currently in stock enter the ranked shortlists. Price and rating history is kept across crawls, so how a listing moved stays on record.

Honest gaps

Missing data is named, not filled

When extracted data is incomplete, the page says exactly what’s missing — “The latest extracted data does not include image variants yet.” — instead of estimating.

Policies

What keeps the ranking honest

No paid placement

Rankings and placement are determined by the scoring model only — never by payment from a brand. This holds for every surface: score cards, top picks, comparison tables, and search results.

  • No sponsored slots, boosted listings, or paid badges
  • Brands cannot pay to be re-scored or re-ranked
  • Commercial terms never reach the scoring pipeline
Advisory & review

How the model changes

No score weight, dose window, or evidence mapping changes quietly. Every change follows the same four-step path.

  1. 01Proposed with rationale

    Every scoring change starts as a written proposal citing the studies or data that motivate it, judged against the evidence standards above.

  2. 02Review

    Independent advisors check ingredient–outcome mappings and dose windows against the underlying research before shipping results.

  3. 03Versioned release

    Approved changes ship behind a new model version, and rankings recompute under it. Each ranking page stamps the snapshot its results were computed from.

  4. 04Logged and correctable

    Every release lands in the changelog below. Found a data error? Report it — corrections are recomputed and noted, not silently patched.

Changelog

Every change to the model

v2.1Apr 2026

Clinical blend recalibrated — ingredient evidence 55% / dose fit 30% / study confidence 15%. A bounded dose-overage reward replaced the old overdose decay.

v2Mar 2026

First versioned ranking profile. Clinical-gated composite, the value/trust/demand reliability gate, and lens shortlists.